This trial should make it possible to establish whether this treatment, administered by suppository, is effective in avoiding hospitalizations.
Article written by
Posted on 09/06/2021 11:27 PM
Reading time: 1 min.
The Institut Pasteur de Lille announced Monday, September 6 that it had recruited its first patient for the second phase of the clinical trial of a possible treatment against Covid-19, clofoctol. And said to research “between 350 and 700 additional patients”, in order to assess the effectiveness of this drug in the early management of Covid-19 patients and the prevention of hospitalizations.
The Institut Pasteur de Lille (which has no link with the one based in Paris) announced the launch of this trial in mid-June, when it had been authorized by the National Medicines Safety Agency.
But “it is only starting now,” Professor Xavier Nassif, director general of the Institute, told AFP. The recruitment of volunteers has indeed been complicated by the summer holidays, by the progress of vaccination and the very precise profile sought: patients over 50 years old, unvaccinated, and presenting at least one symptom.
For the time being, recruitments only concern Hauts-de-France, but “we are trying to extend them to other regions, in particular the West Indies”, explains Xavier Nassif. He believes that this trial remains useful despite the boom in vaccination, “because we do not know how this epidemic will end”, and that “all countries do not have the same access to vaccination.”
Clofoctol should be given to patients as a suppository, twice a day for five days. “Particularly effective in inhibiting the replication of the virus” according to the Institute, the molecule is already marketed in France and in other European countries, in an indication other than that of Covid-19.
Share on Twitter Share on Facebook Share by mail Share the link